Last $120.60 USD
Change Today +0.74 / 0.62%
Volume 84.1K
BIO On Other Exchanges
New York
New York
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

bio-rad laboratories-a (BIO) Key Developments

Bio-Rad Laboratories, Inc. Launches Precision Blue Real-Time PCR Dye

Bio-Rad Laboratories, Inc. has launched its Precision Blue real-time PCR dye. The blue dye improves the visibility of qPCR reaction mixtures, enabling loading of small volume reactions with greater speed, accuracy, and precision. Applications such as single nucleotide polymorphism genotyping and high-throughput gene expression analysis using 384-well plates will particularly benefit from use of this dye. Precision Blue dye is compatible with Bio-Rad's universal qPCR supermixes (iTaq universal and SsoAdvanced universal super mixes) and does not interfere with SYBR Green- or probe-based detection. The dye can be used with all Bio-Rad CFX real-time PCR systems and all other vendors' real-time PCR systems. For convenience, Precision Blue can be added directly to the supermix or used as a component of a reaction master mix. The dye is concentrated 200x, and delivers 500 x 20 µl reactions.

Bio-Rad Laboratories, Inc. Amends and Restates Company's By-Laws

On March 25, 2014, the Board of Directors of Bio-Rad Laboratories, Inc. amended and restated the Company's By-laws dated February 19, 1980. The changes effected by the amendment and restatement of the Company's By-laws include, without limitation, the following: SECTION 2. Registered Office: amended the Company's principle place of business from Richmond, California to Hercules, California; SECTION 5. Annual Meetings: amended the date of the Company's annual meeting of stockholders from the month of April to such date and time as specified by the Board and clarified that any other business to be transacted at the annual meeting of stockholders must be properly brought before the meeting in accordance with the By-laws, that notices of a meeting may be given by electronic transmission and that the Board may postpone, reschedule or cancel any annual meeting of stockholders previously scheduled by the Board; SECTION 6. Special Meetings: amended to specify that special meetings shall be called by the Secretary at the request of not less than a majority of the voting power of the stockholders, that the notice for such special meetings shall state the purposes or purposes for which the meeting is called and to delete a provision that allowed business to be transacted at such special meetings which was not stated in the notice by the unanimous written consent of all stockholders represented at the meeting; SECTION 7. Stockholder List: amended to provide that the list of stockholders entitled to vote at meetings shall be kept at the principle place of the Company's business instead of at a place within the city where the meeting is held, as specified in the notice, of if no notice is specified, then at the place where the meeting is held; SECTION 8. Adjourned Meetings and Notice Thereof: amended to allow any officer entitled to preside at or to act as secretary at any stockholders' meeting to adjourn such meetings and to provide that at the adjourned meeting, the Company may transact any business which might have been transacted at the original meeting; SECTION 9. Voting: amended to create new subsections (a) through (d); SECTION 10. Quorum: amended to add of the outstanding shares of stock of the Company entitled to vote at the meeting. at the end of the first sentence; SECTION 11. Consent of Absentees: amended to provide that written waiver of notice of a meeting of stockholders is not required and that if present at a meeting, a stockholder is deemed to have waived notice unless the stockholder attends the meeting only to object to the transaction of business because the meeting is not lawfully called or convened; SECTION 12. Action Without Meeting: amended to clarify that for actions without a meeting of the stockholders: the executed resolutions have to be delivered to the Company, and notice of written action taken shall only be given to those stockholders who would have been entitled to vote on the matter at a meeting; SECTION 13. Proxies: amended the first sentence to state: Every person entitled to vote at any meeting of stockholders or execute consents to corporate action in writing without a meeting shall have the right to do so either in person or by one or more agents authorized by a written proxy executed by such person or his duly authorized agent and filed with the Secretary of the corporation. SECTION 14. Organization and Conduct of Meetings: added this new section, which addresses the conduct at stockholders' meetings, including that the Chairman of the Board shall act as the chairperson, the Board may designate any other director or officer of the Company to act as chairperson in the absence of the Chairman, the Board may adopt rules and regulations for the conduct at meetings, and except to the extent inconsistent with such rules and regulations, the chairperson shall have the right and authority to convene, recess or adjourn the meeting, to prescribe such rules, regulations and procedures and to do all acts the chairperson deems appropriate for the proper conduct of the meeting, such rules, regulations or procedures, include, without limitation, the agenda, polls, order and safety, limitations on attendance or participation, restrictions on entry and limitations on time allotted to questions or comments, except to the extent determined by the Board or chairperson, meetings shall not be required to be held in accordance with parliamentary procedure.

Bio-Rad Laboratories, Inc. announced delayed annual 10-K filing

On 03/04/2014, Bio-Rad Laboratories, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Bio-Rad Laboratories, Inc. Launches New Antibody Labeling Kits

Bio-Rad Laboratories, Inc. launched its ReadiLink antibody labeling kits, an antibody conjugation solution for labeling microscale amounts, or 50-100 mcg, of antibody. These kits are ideal for researchers interested in labeling their own antibodies for flow cytometry and cell sorting applications. Using the ReadiLink antibody labeling kits, researchers can label their antibodies in two easy steps. The protocol takes only 70 minutes, 30% faster than the next fastest labeling method, and the labels are as bright and photostable as traditional dyes. Bio-Rad offers 10 different fluorophores whose excitation/emission wavelengths range from UV to infrared.

Bio-Rad Laboratories, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Fiscal Year Ended December 31, 2013; Provides Capex Guidance for the Year 2014

Bio-Rad Laboratories, Inc. announced unaudited consolidated earnings results for the fourth quarter and fiscal year ended December 31, 2013. Fourth-quarter 2013 reported revenues were $602.6 million, up 5.0% compared to $573.8 million reported for the fourth quarter of 2012. These results included $6.0 million of sales resulting from the Company's acquisition of AbD Serotec in January 2013. On a currency-neutral basis, quarterly revenues increased 5.7% compared to the same period in 2012. Net income attributable to company was $30.1 million or $1.04 per share on a fully diluted basis compared to $43.3 million or $1.51 per share during the same period in 2012. These results included an accrued expense of $15 million in connection with the Company's efforts to resolve the previously disclosed investigation of the Company in connection with the United States Foreign Corrupt Practices Act; this is in addition to an accrued expense of $20 million in the third quarter of 2013. Income from operations was $52.317 million against $67.114 million a year ago. Income before income taxes was $44.510 million against $59.159 million a year ago. For the full year, the company's sales were $2,132.7 million compared to $2,069.2 million in 2012, an increase of 3.1%, or 3.9% on a currency neutral basis. Net income attributable to company was $77.8 million or $2.69 per share on a fully diluted basis compared to $165.5 million or $5.78 per share in 2012. The decrease in net income in 2013 was primarily due to higher SG&A expenses resulting from employee expenses associated with acquisitions; the $35 million legal accrual, which includes $5 million in interest; and expenses associated with the enterprise resource planning (ERP) implementation. Income from operations was $169.456 million against $264.176 million a year ago. Income before income taxes was $112.385 million against $229.907 million a year ago. Net cash provided by operating activities was $175.476 million against $276.028 million a year ago. Payments for acquisitions and long-term investments were $72.054 million against $39.443 million a year ago. The company also provided capex guidance for the year 2014. For the year 2014, the company expects CapEx spending will be in the $140 million to $150 million range, primarily reflecting the resurgence of investment in deployment 2 of ERP project.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIO:US $120.60 USD +0.74

BIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $35.75 USD +0.19
BioMerieux €76.62 EUR -0.54
PerkinElmer Inc $44.27 USD +0.08
QIAGEN NV €14.80 EUR -0.043
Siemens Ltd 756.50 INR +21.30
View Industry Companies

Industry Analysis


Industry Average

Valuation BIO Industry Range
Price/Earnings 44.8x
Price/Sales 1.6x
Price/Book 1.6x
Price/Cash Flow 36.7x
TEV/Sales 0.8x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-RAD LABORATORIES-A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at